Compare Heron Therapeutics Inc (HRTX) vs H2O America (HTO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Heron Therapeutics Inc vs H2O America — how do they compare? Heron Therapeutics Inc trades at $0.46 (market cap $91.46M), while H2O America trades at $63.79 (market cap $2.70B). The key difference: H2O America is far larger — about 29.5× Heron Therapeutics Inc's market cap, and H2O America pays a 2.73% dividend while Heron Therapeutics Inc pays none. Which is the better fit depends on your goals.
| HRTX | HTO | |
|---|---|---|
Market Cap | $91.46M | $2.70B |
Sector | Health | Technology |
52-Week High | $1.96 | $65.43 |
52-Week Low | $0.39 | $44.44 |
Enterprise Value | $189.36M | $4.42B |
Dividend Yield | — | 2.73% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HRTX trades at $0.48, up 2.06% today, with a bullish technical signal but mixed earnings performance. The company reported Q1 2026 revenue of $151M but missed EPS estimates with a $0.04 loss. Despite negative net income margins, analyst consensus remains overwhelmingly bullish with 18 buy ratings. Recent patent litigation developments and seasonal pressures have impacted quarterly results.
Outlook remains challenged by ongoing losses and competitive pressures, though strong analyst support suggests potential upside if execution improves. Key risks include patent litigation outcomes, cash flow sustainability, and ability to achieve profitability. The stock's low price presents speculative opportunity but requires careful risk management.
HTO trades at $64.52, down 1.39% today, with a bullish technical signal from moving averages and a neutral RSI. The company reported a Q1 2026 EPS beat of $0.50 versus $0.48 expected, with revenue of $816 million in 2026 and a net income margin of 12.86%. A dividend of $0.44 per share is scheduled for payment on June 1, 2026. Analyst consensus is strongly bullish with an 80% buy rating and a $63.50 price target.
The outlook for HTO is positive, supported by steady earnings growth, a reliable dividend, and strong institutional interest. Risks include high capital expenditure demands and sensitivity to regulatory changes in the utilities sector. The stock presents a value opportunity with a P/E of 22.11, trading near analyst targets with potential upside to the high target of $67.00.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Heron Therapeutics Inc
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →About H2O America
H2O America is a utility company that provides essential water and wastewater services, primarily in the United States. The company operates a network of regulated water and wastewater systems, focusing on responsible resource management and high-quality service delivery. HTO aims to expand its operational footprint through acquisitions and internal growth, serving residential, commercial, and industrial customers.
Read more on HTO →
